Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (DE:TD5A)
FRANKFURT:TD5A
TD5A Stock Chart & Stats
Day’s Range― - ―
52-Week Range€16.26 - €48.96
Previous CloseN/A
Volume0.00
Average Volume (3M)139.00
Market Cap
$1.18B
Enterprise Value€2.42B
Total Cash (Recent Filing)$41.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Apr 30, 2025EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding66,473,274
10 Day Avg. Volume150
30 Day Avg. Volume139
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)31.50
P/FCF Ratio44.10
Enterprise Value/Market Cap2.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.58
Enterprise Value/Ebitda-24.32
Forecast
1Y Price Target
€36.56Price Target Upside97.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceTNDM reported non-GAAP WW sales of $252.4mn (+1% vs. consensus $250.6mn), including non-GAAP OUS sales of $68.1mn (+13% vs. consensus $60.3mn).
Growth ProspectsThe results of TNDM's type 2 trial are compelling and will help restore confidence in TNDM's growth prospects.
Market ExpansionExpanded and realigned U.S. distribution and plans to go direct internationally could enhance market reach.
Bears Say
Competitive PressureNew entrants, especially Beta Bionics, are intensifying competition for the #2 spot in the insulin pump market.
Financial PerformanceMargins came in below expectations in Q4, which could stoke anxieties about Tandem’s path to positive EPS.
Share Loss ConcernsTandem appeared to lose share of U.S. type 1 new pump starts in Q4.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.81% Insiders
30.02%
Mutual Funds
43.55% Other Institutional Investors
0.13% Public Companies and
Individual Investors
TD5A FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was €16.25 and its highest was €48.96 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.18B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Apr 30, 2025 which is in 31 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Feb 26, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.189 by €0.198.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.55.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 66,473,274 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.189. Following the earnings report the stock price went down -21.564%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in DE:TD5A
---
Tandem Diabetes Care Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€36.56 (97.42% Upside)
€36.56 (97.42% Upside)
Blogger Sentiment
Bullish
DE:TD5A Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $190.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.55%
12-Months-Change
Fundamentals
Return on Equity
-33.30%
Trailing 12-Months
Asset Growth
1.57%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
---
TD5A Company Deck
---
TD5A Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record sales, the launch of the Control-IQ+ system, and expansion into the type 2 diabetes market. However, challenges remain with U.S. sales shortfalls, potential disruptions from sales force realignment, and international transition complexities. Overall, the positive developments and strategic initiatives indicate strong growth potential, though execution risks exist.Read More>---
TD5A Revenue Breakdown
74.21% U.S.
25.79% International
---
TD5A Stock 12 Month Forecast
Average Price Target
€36.56
▲(97.42% Upside)
Technical Analysis
Best Analysts Covering TD5A
1 Year
1 Year Success Rate
21/28 ratings generated profit
1 Year Average Return
+122.30%
reiterated a buy rating 8 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +122.30% per trade.
---